#Breaking
Same-day regulatory or trial readout coverage.
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.
Browse other coverage
Latest from the blog
Bariatric surgery volumes fell 39%
Epic Cosmos data show US bariatric surgery peaked in Q4 2022 and fell 39% by Q4 2025. Access to GLP-1 agonists before surgery splits sharply by insurance.
BPC-157 and night sweats: what we know
Night sweats appear in BPC-157 user reports but not in any published study. Here is what the evidence and the likely mechanism actually show.
GLP-1 RAs in aging people with HIV
A 2026 review finds semaglutide reduces weight, improves cardiometabolic markers, and may slow epigenetic aging in people with HIV, but key safety gaps remain.
GLP-1R G protein bias via ECL3 displacement
A July 2026 Cell Reports study shows N-terminal modifications to GLP-1R agonists shift signalling toward G protein by displacing extracellular loop 3.
Semaglutide, NAION, and a retracted study
A 2025 paper in Retina on semaglutide and optic nerve risk has been retracted without a stated reason, complicating an already contested safety debate.
Skin Growths, Sermorelin, and BPC-157/TB500
Community reports link sermorelin and BPC-157/TB-500 use to acanthosis. Here is what the IGF-1 and skin-biology literature actually shows.